FGFR2 Gene Craniosynostosis (Nonspecific) Genetic Test in the UAE

Executive Summary & Core Metrics

Executive Summary: This comprehensive FGFR2 NGS test screens the entire FGFR2 gene for pathogenic variants linked to syndromic craniosynostosis—Apert, Crouzon, Pfeiffer syndromes—with 99.9% diagnostic sensitivity. Our ISO 9001:2015 certified laboratory delivers results within 3–4 weeks, supporting DHA‑compliant clinical decision‑making. We offer premium, cold‑chain home blood collection and post‑test telephonic clinical guidance to ensure seamless patient care.

✅ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
🚑 Premium Logistics: Hospital‑Grade Home Collection via ISO Certified Cold‑Chain and VIP Mobile Phlebotomy.
📞 Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation.
💳 Insurance: Direct Billing Verification via WhatsApp +971545488731.

Test Overview & Methodology

This next‑generation sequencing test examines the entire coding region of the FGFR2 gene, identifying both known and novel mutations responsible for syndromic craniosynostosis, providing a definitive molecular diagnosis that guides surgical planning, genetic counselling, and family recurrence risk assessment.

Feature	Our Test (FGFR2 NGS)	Closest Alternative (Sanger Sequencing Hotspot Panel)
Precision & Coverage	99.9% Diagnostic Sensitivity — full gene sequencing, all exons & splice sites	Limited to predefined "hotspot" mutations; may miss ~30% of pathogenic variants
Methodology	Next Generation Sequencing (NGS) with bioinformatic validation and Sanger confirmation	Capillary Sanger sequencing of selected exons only
Turnaround Time	3–4 Weeks	4–6 Weeks
Sample Flexibility	Whole blood, extracted DNA, or one drop of blood on FTA card (cold‑chain not required for FTA)	Whole blood only (requires cold chain)

Physician Insight & Safety Protocols

Lina Osama Zaki Quteineh (DHA Registration ID: 9294403), Consultant Medical Genetics, shares: "I fully appreciate how a potential genetic diagnosis can weigh on a family. This FGFR2 test is a powerful tool to clarify the road ahead, but I urge you to view it as a piece—not the whole—of your child’s clinical picture. Any result must be interpreted alongside physical findings and expert genetic counselling; it never stands alone."

Important Advisory: Medication and Testing Precautions

Do not discontinue any prescribed medication without consulting your physician. This genetic test is a diagnostic aid and does not replace ongoing medical care. Discuss any concerns with your referring clinician before testing.

Exclusion Criteria & Emergency Red Flags

Exclusion: Patients with known somatic mosaicism requiring ultra‑deep sequencing (>1000×) are not suitable for this standard NGS test; alternative testing options may be discussed with a geneticist.
Exclusion: Pregnant individuals require mandatory pre‑test counselling to discuss maternal cell contamination implications.
Emergency Red Flag: If your child shows signs of raised intracranial pressure—repeated vomiting, persistent headache, drowsiness, or bulging fontanelle—seek immediate emergency care. Do not wait for genetic test results.
Emergency Red Flag: Sudden respiratory distress or worsening craniofacial asymmetry warrants urgent specialist evaluation.

Patient FAQ & Clinical Guidance

1. What exactly is an FGFR2 genetic test for craniosynostosis?

It is a DNA sequencing test that reads the entire FGFR2 gene to identify mutations causing premature skull bone fusion, enabling precise diagnosis and family planning. Results should always be interpreted by a clinical geneticist.

2. How is the sample collected and is home service available in the UAE?

Our DHA‑licensed phlebotomists perform a simple blood draw at your home, office, or hotel using cold‑chain transport; a finger‑prick FTA card option is also available for infants. Appointments are available daily from 8 AM to 11 PM.

3. Will my insurance cover this test and how long until I receive results?

Most UAE insurance plans with genetic testing benefits cover this test; we offer direct billing verification via WhatsApp at +971545488731. Results are delivered within 3–4 weeks from sample receipt.

UAE Regulatory & Data Privacy Adherence

This service strictly adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data are stored exclusively on UAE‑based encrypted servers, and patient consent is mandatory before testing. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.

Clinical & Logistical Metadata

Test Name	FGFR2 Gene Craniosynostosis (Nonspecific) Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Whole blood, extracted DNA, or FTA card (cold‑chain not required for FTA)
Methodology Used	Next Generation Sequencing (NGS) with Sanger confirmation
ICD-10-CM Code	Q75.0 (Craniosynostosis), Q75.1 (Craniofacial dysostosis), Q87.0 (Congenital malformation syndromes affecting facial appearance)
LOINC Code	54419-9 (FGFR2 gene mutations found in Blood or Tissue by Molecular genetics method)
DHA Facility License & Laboratory Address	DHA License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| Corporate Lab: DNA Labs UAE